Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Rd
  6. Pre Clinical

Pre-clinical

Thumbnail
May 17, 2022

Vertex’s halt does not deter Sernova and Evotec

Thumbnail
March 23, 2022

Lilly’s oral interleukin exit hints at a dicey future

Liver toxicity with the group’s oral IL-17 inhibitor could raise doubts about projects from Dice, Leo and Sanofi.

Article image
Vantage logo
March 08, 2022

Voyager’s new focus gets more big pharma validation

Article image
Vantage logo
January 10, 2022

JP Morgan 2022 – Beam and Mammoth hook big pharma partners

Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.

Article image
Vantage logo
January 04, 2022

Biogen takes another shot at spinal muscular atrophy

Article image
Vantage logo
December 02, 2021

Investors back Quell’s Treg approach

Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.

Article image
Vantage logo
November 30, 2021

Blueprint takes a long shot at a small niche

Article image
Vantage logo
November 23, 2021

Neurocrine gets selective in schizophrenia

The group’s deal with Sosei will see it compete with Karuna and Cerevel.

Article image
Vantage logo
October 26, 2021

Vertex goes small with Mammoth deal

Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.

Article image
Vantage logo
October 20, 2021

Boehringer takes a different approach in cystic fibrosis gene therapy

Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.

Article image
Vantage logo
September 06, 2021

Another gene therapy safety scare hits

The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.